Chatbot 'Penny' aims to reconnect cancer survivors with life-saving follow-up care
NCT ID NCT05863702
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This study tested a chatbot named Penny that sends text messages to help adult survivors of childhood or young adult cancers schedule follow-up appointments, lab work, and scans. The goal was to see if survivors who had not been to a clinic in over three years would use the chatbot to reengage with care. Fifty-three survivors participated, and researchers tracked how many scheduled and kept their appointments over 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SURVIVORSHIP are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chatbot (Penny)
What this could lead to
If successful, this chatbot could help more cancer survivors get the long-term follow-up care they need, potentially improving their health outcomes.
What could go wrong
This is a small feasibility study with only 53 participants, so results may not apply to everyone. The chatbot relies on text messaging, which may not work for all survivors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.